PET molecular imaging for pathophysiological visualization in Alzheimer’s disease

被引：0
作者：
Jing Wang
Chentao Jin
Jinyun Zhou
Rui Zhou
Mei Tian
Hyeon Jeong Lee
Hong Zhang
机构：
[1] The Second Affiliated Hospital of Zhejiang University School of Medicine,Department of Nuclear Medicine and PET Center
[2] Institute of Nuclear Medicine and Molecular Imaging of Zhejiang University,College of Biomedical Engineering and Instrument Science
[3] Key Laboratory of Medical Molecular Imaging of Zhejiang Province,Key Laboratory for Biomedical Engineering of Ministry of Education
[4] Zhejiang University,undefined
[5] Zhejiang University,undefined
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2023年 / 50卷
关键词：
Alzheimer’s disease; Positron emission tomography (PET); Molecular imaging;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Alzheimer’s disease (AD) is the most common dementia worldwide. The exact etiology of AD is unclear as yet, and no effective treatments are currently available, making AD a tremendous burden posed on the whole society. As AD is a multifaceted and heterogeneous disease, and most biomarkers are dynamic in the course of AD, a range of biomarkers should be established to evaluate the severity and prognosis. Positron emission tomography (PET) offers a great opportunity to visualize AD from diverse perspectives by using radiolabeled agents involved in various pathophysiological processes; PET imaging technique helps to explore the pathomechanisms of AD comprehensively and find out the most appropriate biomarker in each AD phase, leading to a better evaluation of the disease. In this review, we discuss the application of PET in the course of AD and summarized radiolabeled compounds with favorable imaging characteristics.
引用
收藏
页码：765 / 783
页数：18
相关论文
共 962 条
  • [21] Fratiglioni L(2013)Regional variability of imaging biomarkers in autosomal dominant Alzheimer’s disease Proc Natl Acad Sci U S A 110 E4502-58
  • [22] Matthews FE(2013)Preclinical Alzheimer disease—the challenges ahead Nat Rev Neurol 9 54-605
  • [23] Lobo A(2011)New tools for the study of Alzheimer’s disease: what are biomarkers and morphometric markers teaching us? Neuroscientist 17 592-1484
  • [24] Breteler MM(2001)Uncharged thioflavin-T derivatives bind to amyloid-beta protein with high affinity and readily enter the brain Life Sci 69 1471-323
  • [25] Skoog I(2019)Amyloid imaging for differential diagnosis of dementia: incremental value compared to clinical diagnosis and [(18)F]FDG PET Eur J Nucl Med Mol Imaging 46 312-1894
  • [26] Querfurth HW(2009)Preclinical properties of 18F-AV-45: a PET agent for Abeta plaques in the brain J Nucl Med: Off Publ Soc Nucl Med 50 1887-1259
  • [27] Laferla FM(2009)Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease J Nucl Med: Off Publ Soc Nucl Med 50 1251-135
  • [28] Villemagne VL(2008)Imaging of amyloid beta in Alzheimer’s disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism The Lancet Neurol 7 129-598
  • [29] McKhann GM(2015)Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer’s subjects NeuroImage Clinical 9 592-794
  • [30] Knopman DS(2010)Characterization of AZD4694, a novel fluorinated Abeta plaque neuroimaging PET radioligand J Neurochem 114 784-424
12345678910